Last reviewed · How we verify

Liposomal curcumin

University of Florida · FDA-approved active Small molecule

Liposomal curcumin delivers the polyphenol curcumin in lipid nanoparticles to improve bioavailability and enable anti-inflammatory and antioxidant effects.

Liposomal curcumin delivers the polyphenol curcumin in lipid nanoparticles to improve bioavailability and enable anti-inflammatory and antioxidant effects. Used for Cancer supportive care and adjunctive therapy, Inflammatory conditions.

At a glance

Generic nameLiposomal curcumin
Also known asManna Liposomal Curcumin
SponsorUniversity of Florida
Drug classNatural product derivative; anti-inflammatory/antioxidant agent
ModalitySmall molecule
Therapeutic areaOncology; Inflammation; Nutraceutical
PhaseFDA-approved

Mechanism of action

Curcumin is a natural polyphenol from turmeric with pleiotropic biological activities including inhibition of NF-κB signaling, reduction of pro-inflammatory cytokines, and antioxidant effects. The liposomal formulation addresses curcumin's poor oral bioavailability by encapsulating it in lipid vesicles, enhancing cellular uptake and systemic exposure. This allows therapeutic concentrations to be achieved at lower doses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results